|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
CN106267189B
(zh)
|
2010-10-06 |
2021-02-26 |
瑞泽恩制药公司 |
含有抗白介素-4受体(il-4r)的抗体的稳定制剂
|
|
MX385311B
(es)
|
2011-01-28 |
2025-03-18 |
Sanofi Biotechnology |
Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
RU2768492C2
(ru)
|
2011-11-18 |
2022-03-24 |
Ридженерон Фармасьютикалз, Инк. |
Полимерные белковые микрочастицы
|
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR092325A1
(es)
*
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
IL312711A
(en)
|
2012-08-21 |
2024-07-01 |
Regeneron Pharma |
Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
KR102576903B1
(ko)
|
2012-09-07 |
2023-09-13 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
|
|
CN104768578A
(zh)
*
|
2012-10-25 |
2015-07-08 |
米迪缪尼有限公司 |
稳定的低粘度抗体配制品
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
KR20160024906A
(ko)
|
2013-06-07 |
2016-03-07 |
사노피 바이오테크놀로지 |
Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
|
|
KR20210132232A
(ko)
*
|
2013-06-21 |
2021-11-03 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
|
|
TWI634900B
(zh)
*
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
US10935554B2
(en)
|
2013-08-23 |
2021-03-02 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
|
|
EP3068803B1
(en)
|
2013-11-12 |
2021-01-20 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
KR102927870B1
(ko)
|
2014-02-28 |
2026-02-19 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
|
|
CN107206068A
(zh)
|
2014-07-16 |
2017-09-26 |
赛诺菲生物技术公司 |
用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
|
|
AU2015310879A1
(en)
*
|
2014-09-03 |
2017-03-02 |
Medimmune Limited |
Stable anti-IL-4R-alpha antibody formulation
|
|
WO2016077675A1
(en)
|
2014-11-14 |
2016-05-19 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
KR20240172758A
(ko)
|
2015-08-18 |
2024-12-10 |
리제너론 파아마슈티컬스, 인크. |
지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
|
|
AU2017220184B2
(en)
|
2016-02-19 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
|
|
KR20240052871A
(ko)
|
2016-04-27 |
2024-04-23 |
애브비 인코포레이티드 |
항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
|
|
CN113372446A
(zh)
|
2016-06-08 |
2021-09-10 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
US11771743B2
(en)
|
2016-09-01 |
2023-10-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an IL-4R antagonist
|
|
US10485844B2
(en)
|
2016-09-22 |
2019-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
|
|
KR20190053250A
(ko)
|
2016-09-22 |
2019-05-17 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
KR20190090820A
(ko)
|
2016-11-29 |
2019-08-02 |
리제너론 파아마슈티컬스, 인크. |
오피오이드 중독 방지를 위한 약학 조성물
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
US11352417B2
(en)
|
2016-12-22 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
TWI716668B
(zh)
|
2017-02-01 |
2021-01-21 |
耶魯大學 |
心臟衰竭及心腎症候群之精準治療
|
|
JP6172880B1
(ja)
*
|
2017-02-01 |
2017-08-02 |
協和発酵キリン株式会社 |
ダルベポエチンを含む液体医薬組成物
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
JOP20190260A1
(ar)
*
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
EP3703818B1
(en)
|
2017-10-30 |
2023-11-01 |
Sanofi Biotechnology |
Il-4r antagonist for use in a method for treating or preventing asthma
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
MX2020006882A
(es)
|
2018-01-05 |
2020-09-07 |
Novo Nordisk As |
Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
|
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
CA3108697A1
(en)
|
2018-08-10 |
2020-02-13 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
CN113056482A
(zh)
*
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
CN113166259A
(zh)
|
2018-11-09 |
2021-07-23 |
亚洲大学校产学协力团 |
对人IL-4受体α具有高亲和力的人抗体及其用途
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
PL3857237T3
(pl)
|
2019-01-16 |
2023-07-10 |
Regeneron Pharmaceuticals, Inc. |
Sposoby charakteryzowania mostka disiarczkowego
|
|
SG11202108627SA
(en)
|
2019-02-18 |
2021-09-29 |
Lilly Co Eli |
Therapeutic antibody formulation
|
|
AU2020231343B2
(en)
|
2019-03-06 |
2026-03-26 |
Regeneron Pharmaceuticals, Inc. |
IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
CN111686247B
(zh)
*
|
2019-03-13 |
2022-07-29 |
苏州康乃德生物医药有限公司 |
包含人白介素-4受体α的抗体的液体组合物
|
|
TW202519263A
(zh)
*
|
2019-03-21 |
2025-05-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
|
SG11202109002XA
(en)
|
2019-03-21 |
2021-09-29 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
KR20220004708A
(ko)
|
2019-05-01 |
2022-01-11 |
사노피 바이오테크놀로지 |
Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법
|
|
AU2020275406A1
(en)
|
2019-05-13 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
CA3147436A1
(en)
|
2019-07-16 |
2021-01-21 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
EP4010373A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
AU2020325021B2
(en)
|
2019-08-05 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
IL291020B2
(en)
|
2019-09-24 |
2025-04-01 |
Regeneron Pharma |
Systems and methods for use in chromatography and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
IL293487A
(en)
|
2019-12-09 |
2022-08-01 |
Sanofi Biotechnology |
Methods for the treatment of digitally identified il-4/il-13-related disorders
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
CA3162507A1
(en)
|
2019-12-23 |
2021-07-01 |
Helene Goulaouic |
Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
|
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
JP7752620B2
(ja)
*
|
2020-02-21 |
2025-10-10 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｉｌ－４ｒ抗体医薬組成物及びその使用
|
|
KR20220158821A
(ko)
|
2020-03-27 |
2022-12-01 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
IL298257A
(en)
|
2020-05-22 |
2023-01-01 |
Regeneron Pharma |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
CN113797331A
(zh)
*
|
2020-06-16 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种稳定的抗IL-4Rα单克隆抗体液体制剂
|
|
KR20230035595A
(ko)
*
|
2020-07-08 |
2023-03-14 |
리제너론 파아마슈티컬스, 인크. |
항-ctla-4 항체를 함유하는 안정화된 제형
|
|
IL300828A
(en)
|
2020-08-31 |
2023-04-01 |
Regeneron Pharma |
Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
|
|
MX2023003942A
(es)
|
2020-10-05 |
2023-06-02 |
Sanofi Biotechnology |
Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
MX2023007945A
(es)
|
2021-01-08 |
2023-09-21 |
Regeneron Pharma |
Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
MX2023010837A
(es)
|
2021-03-17 |
2023-09-29 |
Receptos Llc |
Métodos de tratamiento de la dermatitis atopica.
|
|
CA3211302A1
(en)
|
2021-03-26 |
2022-09-29 |
Ross Kenyon |
Methods and systems for developing mixing protocols
|
|
TW202304507A
(zh)
*
|
2021-04-02 |
2023-02-01 |
美商再生元醫藥公司 |
含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
WO2023009437A1
(en)
|
2021-07-26 |
2023-02-02 |
Sanofi Biotechnology |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
|
KR20240049351A
(ko)
|
2021-08-23 |
2024-04-16 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
US20240343815A1
(en)
*
|
2021-08-26 |
2024-10-17 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pharmaceutical composition of anti-il4r antibody and use thereof
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CA3232463A1
(en)
*
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
JP2024538673A
(ja)
|
2021-10-07 |
2024-10-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨモデリング及び制御のシステム及び方法
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
US20230183362A1
(en)
|
2021-10-20 |
2023-06-15 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
US20250011408A1
(en)
|
2021-11-19 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
CN118355034A
(zh)
|
2021-12-30 |
2024-07-16 |
瑞泽恩制药公司 |
施用il-4/il-13拮抗剂以减弱特应性进程的方法
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
WO2023212586A1
(en)
|
2022-04-27 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
IL316264A
(en)
*
|
2022-05-02 |
2024-12-01 |
Regeneron Pharma |
Antibody formulations against interleukin-4 receptor (IL-4R)
|
|
CA3259540A1
(en)
|
2022-07-08 |
2024-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
|
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
CN120187754A
(zh)
|
2022-11-01 |
2025-06-20 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗手足皮炎的方法
|
|
EP4622669A1
(en)
|
2022-11-23 |
2025-10-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
CN120418653A
(zh)
|
2022-12-16 |
2025-08-01 |
里珍纳龙药品有限公司 |
评估色谱柱完整性的方法和系统
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
EP4683942A1
(en)
|
2023-03-22 |
2026-01-28 |
Sanofi Biotechnology |
Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
|
|
CN121001741A
(zh)
|
2023-03-27 |
2025-11-21 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
|
|
EP4687971A1
(en)
*
|
2023-03-30 |
2026-02-11 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
CN119215163A
(zh)
*
|
2023-06-30 |
2024-12-31 |
百奥泰生物制药股份有限公司 |
抗IL-4Rα抗体制剂及其制备方法和应用
|
|
WO2025017034A1
(en)
|
2023-07-17 |
2025-01-23 |
Formycon Ag |
Stable liquid antibody formulation for dupilumab
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025075970A1
(en)
|
2023-10-02 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Drug delivery device safety system
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025116648A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
|
|
WO2025116640A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
|
|
WO2025116637A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 액상 제형
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
EP4623903A1
(en)
|
2024-03-28 |
2025-10-01 |
Fresenius Kabi Deutschland GmbH |
Pharmaceutical composition comprising dupilumab
|
|
TW202607027A
(zh)
|
2024-04-15 |
2026-02-16 |
法商賽諾菲生物技術公司 |
藉由施用ｉｌ－４ｒ拮抗劑治療慢性鼻竇炎不伴鼻息肉之方法
|
|
CN118105485B
(zh)
*
|
2024-04-26 |
2024-09-03 |
湖南麦济生物技术有限公司 |
一种稳定的抗人IL-4Rα单克隆抗体制剂
|
|
WO2025247342A1
(zh)
*
|
2024-05-30 |
2025-12-04 |
重庆智翔金泰生物制药股份有限公司 |
包含抗il-4r抗体的药物组合物
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
US20260070995A1
(en)
|
2024-09-09 |
2026-03-12 |
Marcella Ruddy |
Methods for treating bullous pemphigoid by administering an il-4r antagonist
|
|
WO2026059949A1
(en)
|
2024-09-10 |
2026-03-19 |
Sanofi Biotechnology |
Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|